Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Summary

The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.

Timeline

Start

2023-08-03

Primary completion

2024-05-21

Completion

2024-09-19

Publications

• Hastie A, Gupta V, Lese P, Moya J, Schoonbroodt S, Beudjekian S, Struyf F. Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial. Hum Vaccin Immunother. 2026 Dec;22(1):2649314. doi: 10.1080/21645515.2026.2649314. Epub 2026 Jun 11.

Drugs

Indications